Avitar to Host Construction Safety & Drug Abuse Executive Roundtable
16 February 2006 - 12:30AM
PR Newswire (US)
Senior Construction and Risk Management Executives to Share
Experiences and Perspectives CANTON, Mass., Feb. 15
/PRNewswire-FirstCall/ -- Avitar, Inc., (OTC:AVRN) (BULLETIN BOARD:
AVRN) , developer of the world's first on-site, oral test for
drugs-of-abuse, is hosting a construction safety and drug abuse
executive roundtable that will feature prominent spokespeople from
across the Construction, Risk Management and Insurance industries.
The event will take place on February 27, 2006 from 9:30 am to
12:30 pm at the Newton Marriott, Newton, MA. Steve Turko, National
Accounts Director for Construction of Avitar will moderate the
roundtable. "The direct correlation between drug abuse and safety
at construction sites is well established. While there are many
benefits to reducing employee drug use, one of the most important
is reducing the number of preventable on- the-job accidents," Peter
P. Phildius, Chairman and CEO, commented. "The profile of the
participants and audience of this executive roundtable is a
testament to the fact that organizations across the country are
realizing the devastating effects of employee drug use and they are
serious about implementing innovative programs to address the
problem." Roundtable participants include: * Perini Corp, Roger
Bruce, Corporate Safety Director * Gilbane Building Company, Tony
O'Dea, Corporate Safety Manager * Impact, Robert Banks, Director *
The Facchina Group of Companies, Joseph J. Poliafico, Director,
Risk Management and Human Resources * Aon Risk Services, Glenn
Narrow, Senior Risk Control Specialist Discussions will focus on
current and future trends, as well as participants' experiences
with drug-free workplace programs, drug testing and their impacts
upon job site safety. Individuals wishing to attend the event can
visit Avitar at http://www.avitarinc.com/ for registration
information. About Avitar Avitar, Inc. develops, manufactures and
markets innovative and proprietary products. Their field includes
the oral fluid diagnostic market, the disease and clinical testing
market, and customized polyurethane applications used in the wound
dressing industry. Avitar manufactures ORALscreen(R), the world's
first non-invasive, rapid, onsite oral fluid test for
drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical
dressing for moderate to heavy exudating wounds. Avitar is also
developing diagnostic strategies for disease and clinical testing
in the estimated $25 billion in-vitro diagnostics market.
Conditions targeted include influenza, diabetes, and pregnancy. For
more information, see Avitar's website at
http://www.avitarinc.com/. Company Contact: PR Contact: Peter
Cholakis Maura Landry Avitar Inc. SHIFT Communications 781-821-2440
x117 617-681-1229 First Call Analyst: FCMN Contact: DATASOURCE:
Avitar, Inc. CONTACT: Peter Cholakis of Avitar Inc.,
+1-781-821-2440, ext. 117, ; or Maura Landry of SHIFT
Communications for Avitar Inc., +1-617-681-1229, Web site:
http://www.avitarinc.com/
Copyright